No Data
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Stoke Therapeutics' Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results
Stoke Therapeutics Analyst Ratings
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24
Stoke Therapeutics Negative Reaction After STK-001 Update Overdone, Says Chardan
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
